ADC · HER2+ 유방암

40개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved40 programs
ADCCurated CoreFDAGileadSN-38 (topoisomerase I inhi…Approved

sacituzumab govitecan (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy)

Metastatic triple-negative breast cancer, pretreated HR+/HER2− breast cancer · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 242Status Approved
ADCCurated CoreFDADaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 240Status Approved
ADCCurated CoreFDARocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 178Status Approved
ADCCurated CoreFDADaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk)

HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
ADCStandard DatabaseFDAstaleDaiichi SankyoApproved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Approved#FDA-approved#antibody-drug-conjugate+3
Trials 24Status Approved
ADCLimited DatastaleRochederuxtecan (Dato-DXd, Datro…Phase 3

T-DXd (Trastuzumab-Deruxtecan, Trastuzumab-Deruxtecan (T-DXd))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+3
Trials 134Status Recruiting
ADCStandard DatabasestaleRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#Popular#antibody-drug-conjugate+4
Trials 127Status Discontinued
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 124Status Recruiting
ADCLimited DatastaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan (T-DXd) with pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Approved#Popular#antibody-drug-conjugate+3
Trials 124Status Recruiting
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 122Status Recruiting
ADCLimited DatastaleShanghai Fosun Pharmaceutical I…DM1 via butelase-1 with ABD…Phase 3

Kadcyla, T-DM1 (Control drug: Trastuzumab emtansine, Control drug: Trastuzumab emtansine (Kadcyla, T-DM1))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+3
Trials 84Status Active
ADCLimited DatastaleRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Ado-trastuzumab emtansine, Ado-trastuzumab emtansine (T-DM1))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+3
Trials 61Status Recruiting
ADCStandard DatabasestaleRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Trastuzumab emtansine, Trastuzumab emtansine (T-DM1))

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · HER2

#HER2#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 59Status Recruiting
ADCStandard DatabasestaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Breast Neoplasms; Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+3
Trials 29Status Recruiting
ADCStandard DatabasestaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#antibody-drug-conjugate#Byondis
Trials 23Status Active
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#antibody-drug-conjugate#NeoadjuvantTherapy+1
Trials 17Status Active
ADCStandard DatabasestaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#HER2+BreastCancer+1
Trials 17Status Recruiting
ADCStandard DatabasestaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 11Status Recruiting
ADCStandard DatabasestaleQuantumLeap Healthcare Collabor…Phase 2

[vic-]trastuzumab duocarmazine (SYD985, SYD985 ([vic-]trastuzumab duocarmazine))

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 7Status Recruiting

1 / 2 pages

← PreviousNext →